NASDAQ · DRUG
Bright Minds Biosciences Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DRUG: Dec 22, 2026
Bright Minds Biosciences Inc. Common Stock is estimated to report earnings on 12/22/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.07. The reported EPS for the same quarter last year was $-0.41.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.07 | $-0.76 | $-1.38 | 2 |
| Dec 2026 | $-1.09 | $-0.87 | $-1.30 | 2 |
| Mar 2027 | $-1.31 | $-1.05 | $-1.57 | 2 |
| Jun 2027 | $-1.33 | $-1.27 | $-1.38 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · Fintel · RTTNews- Zacks · Aug 27, 12:00 PM EDTWhat Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 26, 9:55 AM EDTWall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the st
- Zacks · Aug 10, 9:55 AM EDTWall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a BetThe mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Jul 23, 9:55 AM EDTWall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Jul 22, 12:00 PM EDTAll You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong BuyBright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- The Motley Fool · May 21, 5:51 PM EDTWhy a $5 Million New Position Signals Confidence in This Epilepsy Drug PipelineB Group bought 67,500 shares of Bright Minds Biosciences in the first quarter.
- Fintel · Apr 13, 8:04 PM EDTJefferies Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationFintel reports that on April 13, 2026, Jefferies initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a Buy recommendation. Analyst Price Forecast Suggests 89.70% Downside
- RTTNews · Jan 6, 2:00 PM ESTBright Minds Stock Surges 22% After Positive Phase 2 Topline Results(RTTNews) – Bright Minds Biosciences Inc. (DRUG) shares rose 22.35%, trading at $97.89, up $17.88, following the company's announcement of positive topline results from its Phase 2 clinical trial.
- RTTNews · Jan 6, 4:04 AM ESTBright Minds To Unveil Topline Results For BMB-101 Phase 2 Trial In Absence Seizures And DEE(RTTNews) – Bright Minds Biosciences Inc. (DRUG), a clinical-stage biotechnology company, announced that it will host a conference call and live webcast at 8:00 AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 dubbed the BREAKTHROUGH study in p
- RTTNews · Jan 5, 9:23 PM ESTAfter-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains(RTTNews) – Several biotechnology and pharmaceutical names posted notable gains in after-hours trading on Monday, driven by clinical trial updates, regulatory progress, and investor anticipation ahead of key data releases.
- Zacks · Nov 26, 8:55 AM ESTRecent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's WhyBright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- Zacks · Nov 25, 9:55 AM ESTWall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Bright Minds Biosciences Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.